A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis (IXORA-S)

The main purpose of this study is to evaluate the efficacy of the study drug ixekizumab compared to ustekinumab in participants with moderate-to-severe-plaque psoriasis.


Study Type: Interventional  (Clinical Trial)
Actual Enrollment: 302 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A 52-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Ustekinumab in Patients With Moderate-to-Severe Plaque Psoriasis
Study Start Date: October 2015
Actual Primary Completion Date: May 2016
Actual Study Completion Date: October 2017

Arms:
- Active Comparator: Ustekinumab
- Experimental: Ixekizumab


Related journal:
- Ixekizumab provides superior efficacy compared with ustekinumab over 52-weeks of treatment: results from IXORA-S, a phase 3 study.